Linoleyl carbonate-paclitaxel conjugate - Luitpold Pharmaceuticals

Drug Profile

Linoleyl carbonate-paclitaxel conjugate - Luitpold Pharmaceuticals

Alternative Names: 2-linoleyl carbonate-paclitaxel; LOC-pac; LOC-paclitaxel

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luitpold Pharmaceuticals
  • Developer Luitpold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Metastatic disease) in USA (IV, Infusion)
  • 01 Feb 2016 Luitpold Pharmaceuticals terminates a phase I trial in Malignant melanoma (Metastatic disease, Second-line therapy or greater) in USA due to early positive results (NCT01039844)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top